Nova

InsightRX to Showcase Precision Dosing Technology at ASHP 2022 Midyear Meeting

Retrieved on: 
Thursday, December 1, 2022

SAN FRANCISCO, Dec. 1, 2022 /PRNewswire/ -- Today, InsightRX — which provides cloud-based precision dosing support to guide treatment decisions – announced its slate of activities and demonstrations during the American Society of Health-System Pharmacists (ASHP) 2022 Midyear Clinical Meeting and Exhibition in Las Vegas from Dec. 4-8.

Key Points: 
  • SAN FRANCISCO, Dec. 1, 2022 /PRNewswire/ -- Today, InsightRX which provides cloud-based precision dosing support to guide treatment decisions announced its slate of activities and demonstrations during the American Society of Health-System Pharmacists (ASHP) 2022 Midyear Clinical Meeting and Exhibition in Las Vegas from Dec. 4-8.
  • At ASHP Midyear, held at the Mandalay Bay Convention Center, they will be showcasing several new therapeutic categories that are now a part of their offering.
  • 2020 brought the newest vancomycin consensus guidelines ,which firmly recommended Bayesian forecasting software as the preferred method of dosing and monitoring.
  • InsightRX is a healthcare technology company that has developed a cloud-based platform for precision medicine and clinical analytics designed to individualize treatment at the point of care.

Wellbeing Subsidiary KGK Science Submits CTA for Phase IIA Clinical Trial

Retrieved on: 
Wednesday, November 30, 2022

This is certainly an exciting time for KGK Science and our client Nova Mentis as we await Health Canadas review of this pioneering Phase IIa psilocybin microdose study, commented Najla Guthrie, CEO of Wellbeing Digital & KGK Science.

Key Points: 
  • This is certainly an exciting time for KGK Science and our client Nova Mentis as we await Health Canadas review of this pioneering Phase IIa psilocybin microdose study, commented Najla Guthrie, CEO of Wellbeing Digital & KGK Science.
  • The CTA is subject to a 30-day review by Health Canada, and if approval is granted, KGK intends to start the clinical study in early 2023.
  • The submission of the CTA is a significant milestone in the clinical development of Nova Mentis proprietary drug called NM-1001, said William Rascan, President & CEO of Nova Mentis.
  • Subsidiary of Wellbeing Digital Sciences, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products.

Nova LifeStyle, Inc. Reports Third Quarter FY 2022 Results

Retrieved on: 
Friday, November 18, 2022

LOS ANGELES, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Nova LifeStyle, Inc.(NASDAQ: NVFY) (Nova LifeStyle or the Company) today announced its financial results for the third quarter endedSeptember 30, 2022.

Key Points: 
  • LOS ANGELES, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Nova LifeStyle, Inc.(NASDAQ: NVFY) (Nova LifeStyle or the Company) today announced its financial results for the third quarter endedSeptember 30, 2022.
  • Gross profit was $1.1 million, compared toa gross profit of $1.4 million in the same period of 2021.
  • Tawny Lam, Chairperson and Chief Executive Officer ofNova LifeStyle, stated, We increased sales in the third quarter during a challenging operating environment.
  • Nova LifeStyles product lines include the Nova Brands and Diamond Sofa ( www.diamondsofa.com ).

Qualis Innovations Inc. recently announces its financial results along with updated form Company’s Chief Executive

Retrieved on: 
Thursday, November 17, 2022

Chadds Ford, Pennsylvania, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Qualis Innovations Inc. currently trades under symbol QLIS, recently announced its financial 10-Q report on November 14, 2022.

Key Points: 
  • Chadds Ford, Pennsylvania, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Qualis Innovations Inc. currently trades under symbol QLIS, recently announced its financial 10-Q report on November 14, 2022.
  • Dr. Joseph Pergolizzi provided the following update to the Companys progress and direction
    As acting Chief Executive Officer of Qualis Innovations, I want to thank you for your support for Qualis Innovations and for your loyalty and patience while we work to build value in your company.
  • I am an experienced C-suite executive who brings an extensive professional network and background in global healthcare to Qualis.
  • Please visit our SEC filings or Company's website for more information on the full results and management's plan.

Emera Inc. Subsidiary Nova Scotia Power Reaches Settlement Agreement on General Rate Application, Including Fuel and Non-fuel Rates for 2023 and 2024

Retrieved on: 
Thursday, November 24, 2022

Emera Inc. (TSX: EMA) and its wholly-owned subsidiary Nova Scotia Power (NS Power) announced today that NS Power has filed a proposed settlement agreement for its 2022-2024 General Rate Application (GRA) with the Nova Scotia Utility and Review Board (UARB).

Key Points: 
  • Emera Inc. (TSX: EMA) and its wholly-owned subsidiary Nova Scotia Power (NS Power) announced today that NS Power has filed a proposed settlement agreement for its 2022-2024 General Rate Application (GRA) with the Nova Scotia Utility and Review Board (UARB).
  • If approved by the UARB, the settlement will implement Bill 212, the provincially legislated cap on non-fuel rates for 2023 and 2024.
  • Nova Scotia Power Inc. is a wholly-owned subsidiary of Emera Inc. (TSX-EMA), a diversified energy and services company.
  • Nova Scotia Power provides 95% of the generation, transmission and distribution of electrical power to approximately 540,000 residential, commercial and industrial customers across Nova Scotia.

Wellbeing Subsidiary KGK Science Enters into Research Contract With Nova Mentis for Phase II A Clinical Trial

Retrieved on: 
Thursday, November 17, 2022

The pioneering Phase II clinical trial is the first human research investigating the potential of a microdose of psilocybin to improve behavioural and cognitive symptoms associated with Fragile X syndrome.

Key Points: 
  • The pioneering Phase II clinical trial is the first human research investigating the potential of a microdose of psilocybin to improve behavioural and cognitive symptoms associated with Fragile X syndrome.
  • Under the research and services agreement with Nova Mentis, KGK will perform research services, including the development of the clinical trial protocol, regulatory and ethics submissions, conduct of the trial, data management and validation, statistical analysis and drafting of the final report (Services).
  • The clinical trial is planned to be conducted at KGKs dedicated research facility in London, Ontario, Canada.
  • Subsidiary of Wellbeing Digital Sciences, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products.

NOVA Chemicals Commits $600,000 to Let’s Talk Science to support STEM Education across Canada

Retrieved on: 
Thursday, November 10, 2022

This multi-year financial commitment will support STEM education for children and youth across Canada, regardless of gender, geography, culture, language, abilities, and financial status.

Key Points: 
  • This multi-year financial commitment will support STEM education for children and youth across Canada, regardless of gender, geography, culture, language, abilities, and financial status.
  • We are very grateful for the ongoing support and commitment of NOVA Chemicals, stated Dr. Bonnie Schmidt, President and Founder of Lets Talk Science.
  • With support from NOVA Chemicals, Lets Talk Science will advance our mission to equip todays youth with the skills they need for future jobs and citizenship demands.
  • To accomplish this, Lets Talk Science offers a comprehensive suite of STEM based programs to support youth, educators, families and volunteers across Canada.

The Global Extrusion Coatings Market is expected to grow by $ 1.53 bn during 2022-2026, accelerating at a CAGR of 5.26% during the forecast period

Retrieved on: 
Thursday, November 10, 2022

Key Points: 
  • Also, the popularity of additive manufacturing and increasing applications of extrusion coatings in various industries will lead to sizable demand in the market.
  • The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
  • Technavios market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Latest Mirantis OpenStack for Kubernetes Adds Security, Enhances Usability, and Storage Management

Retrieved on: 
Tuesday, November 8, 2022

Mirantis , freeing developers to create their most valuable code, today announced an update to Mirantis OpenStack for Kubernetes (MOSK) that delivers early access to production-grade OpenStack Yoga, delivers new security features, improves backups and storage management making it easier than ever to run resilient OpenStack clouds at scale.

Key Points: 
  • Mirantis , freeing developers to create their most valuable code, today announced an update to Mirantis OpenStack for Kubernetes (MOSK) that delivers early access to production-grade OpenStack Yoga, delivers new security features, improves backups and storage management making it easier than ever to run resilient OpenStack clouds at scale.
  • It removes the typical challenges of OpenStack cluster deployment and operations with an easy-to-use virtualization platform containerized and optimally configured for Kubernetes.
  • MOSK enables digital infrastructure for cloud native and traditional applications which ensures reliability and enables full control over data.
  • MOSK provides centralized logging, monitoring, and alerting, along with tooling to automate management of the underlying infrastructure, from server provisioning to software configuration.

Practice Interactive Bolsters Healthcare Innovation Across Tech, Wellness, Supplements

Retrieved on: 
Tuesday, November 1, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221101006030/en/
    The Practice Interactive Group of companies work together and independently to improve the health of healthcare.
  • Practice Interactive is headquartered in Austin, Texasa hotbed for industry trailblazerswith three core entities: Intiva Health, Nova Vita Wellness Centers, and Gummi World.
  • The group of companies creates visionary solutions in software, clinical practice, and nutraceutical manufacturing which offer minimal-risk growth strategies under the umbrella of healthcare.
  • At Practice Interactive, we believe that the healthcare industry is in need of a transformation.